



**Living Cell Technologies Ltd**

**COMPANY ANNOUNCEMENT**

**Living Cell Technologies Reports Interim Results Showing Sustained Benefit With DIABECCELL® Implants for Insulin Dependent Diabetes**

**February 11, 2009 – Sydney, Australia, Auckland, New Zealand– Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY)** reports positive interim results from the long term follow-up of insulin dependent diabetes patients in the Phase I/IIa clinical trial of its lead product, DIABECCELL®.

A total of seven patients have received DIABECCELL® implants, five of whom have had two low dose (5,000 islet equivalents (IEQs) per kg body weight) implants at least six months apart. There have been no remarkable adverse events attributed to double implants. Two patients have received a single higher dose (10,000 IEQs/kg) with no safety concerns to date.

The results of 36 to 68 weeks follow-up from the first four patients showed that good blood glucose control was maintained as reflected by a reduction in glycated hemoglobin (% HbA1c) levels from a mean of 8% pre-enrolment to 6.8% at time of clinical review. The American Diabetes Association target for good blood glucose control is HbA1c below 7% and the normal is less than 6.2%. This control was attained despite a reduction of 10% - 38% in the required daily insulin dose.

It is too early to assess the second implant for the fifth patient. However, the patient's HbA1c improved markedly from 9.8% before enrolment to 7.2% accompanied with a small reduction in the average daily insulin dose of 6%.

LCT Medical Director, Professor Bob Elliott said, "The patients clearly benefited from the implants administered at the lowest dose. The second implant maintained this benefit. Remarkably none of the patients have had problems with clinically relevant episodes of low blood glucose. Most people with diabetes cannot attain this degree of blood glucose control shown by these patients without large swings of very low or high blood glucose levels that are often fatal."

Two more patients have received the higher dose of DIABECCELL®. Patient six declined further follow-up at 20 weeks after the first implant when there was no change in glucose control or insulin dose. To improve consistency, LCT narrowed product quality release specifications for all subsequent implants. Patient seven has been followed up for only four weeks at which time HbA1c improved dramatically from 8.3% to 4.8% and daily insulin requirement dropped by 60%.

Professor Elliott further stated, "We can expect better outcomes with higher doses. The encapsulated cells offer not only an alternative but a physiological replacement therapy to provide new hope and improved lifestyles for people with diabetes."

Dr Paul Tan, LCT Chief Executive Officer, said, "The next three patients in Russia are scheduled to receive the 10,000 IEQ/kg dose by April this year before testing the top dose of 15,000 IEQs/kg. Steps to initiate a pivotal trial and a commercialization strategy in Russia have been taken."

DIABECCELL® is LCT's encapsulated porcine insulin-producing cell product designed for the treatment of type 1 diabetes without the use of immunosuppressive drugs.

-Ends-



**For further information:**

Dr. Paul Tan  
Chief Executive Officer  
Mob: 0402 716 984 (AUS)  
Mob: 021 608 784 (NZ)  
Tel: +64 9 270 794

Mr John Cowan  
Finance & Administration Manager  
Tel: +64 9 276 2690  
[jcowan@lctglobal.com](mailto:jcowan@lctglobal.com)

Dr. Bob Elliott  
Medical Director  
Mob: +64 27 292 4177  
Tel: +64 9 276 2690  
[relliott@lctglobal.com](mailto:relliott@lctglobal.com)

Rebecca Wilson  
Investor and Media Relations (ANZ)  
Mob: +61 417 382 391  
Tel: +61 3 9866 4722  
[rwilson@bcg.com.au](mailto:rwilson@bcg.com.au)

**About Living Cell Technologies:** [www.lctglobal.com](http://www.lctglobal.com)

*Living Cell Technologies (LCT) is developing cell-based products to treat life threatening human diseases. The Company owns a biocertified pig herd that it uses as a source of cells for treating diabetes and neurological disorders. For patients with type 1 diabetes, the Company transplants microencapsulated islet cells so that near-normal blood glucose levels may be achieved without the need for administration of insulin or at significantly reduced levels. The company entered clinical trials for its diabetes product in 2007. For the treatment of Huntington's disease and other neurological disorders, the company transplants microencapsulated choroid plexus cells that deliver beneficial proteins and neurotrophic factors to the brain. LCT's technology enables healthy living cells to be injected into patients to replace or repair damaged tissue without requiring the use of immunosuppressive drugs to prevent rejection. LCT also offers medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes.*

**LCT Disclaimer**

This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information as of December 2008 and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.